Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing

Medicare is requesting outcome data on patients who received Prolaris testing and were prescribed active surveillance (AS). In order to ensure appropriate patient care, it is important to understand how this added prognostic information influences the selection and durability of AS and corresponding clinical outcomes. To address this knowledge gap, this study will evaluate how frequently men with low disease-specific mortality (DSM) risk based on Prolaris CCR score and who meet NCCN low-risk criteria initially select AS (AS selection). This study also will assess how long Prolaris-tested men who initially select AS remain on this course before proceeding to definitive treatment (AS durability), and whether AS duration impacts biochemical recurrence (BCR) and metastasis risk in these men. This retrospective, observational and multi-site study will combine patient CCR scores with longitudinal clinical data to address these questions.

Sex

Male

Maximum age

80 Years

Inclusion Criteria:

* Diagnosed with localized PrCa at participating sites between January 1, 2013 and August 1, 2017.
* Have undergone Prolaris testing and have a CCR score with estimated DSM risk ≤3.2%.
* Have NCCN low-risk disease2.

Exclusion Criteria:

* Received any therapy other than 5α-reductase inhibitor (5-ARI) prior to diagnostic biopsy.
* Over 80 years of age at diagnosis.
* History of hypogonadism at the time of diagnosis.
* Co-occurring malignancy, excluding non-melanoma skin cancer.
* Enrolled in another investigational study.